Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

New research helps explain why a subset of patients with relapsing/remitting multiple sclerosis (MS) experience long-term heart rate slowing after taking fingolimod.

On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

By attending multiple sclerosis (MS) support group meetings, getting to know members, and sharing their drug-company–sponsored meals, an author delves into the group’s culture and determination to resist being pigeonholed.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System, spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis (MS).

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).